Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 50, 1121-1124, February 15, 1990]
© 1990 American Association for Cancer Research
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tada, M.
Right arrow Articles by Ohto, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tada, M.
Right arrow Articles by Ohto, M.

Analysis of ras Gene Mutations in Human Hepatic Malignant Tumors by Polymerase Chain Reaction and Direct Sequencing

Minoru Tada, Masao Omata1 and Masao Ohto

First Department of Internal Medicine, Chiba University School of Medicine, Chiba 280, Japan

The ras gene is one of the oncogenes most commonly detected in human cancers, and it consists of three families (H-ras, K-ras, N-ras). These genes are converted to active oncogenes by point mutations occurring in either codon 12, 13, or 61. We analyzed mutations of these codons in 23 primary hepatic malignant tumors (12 hepatocellular carcinomas, nine cholangiocarcinomas, and two hepatoblastomas) by a method to directly sequence nucleotides, using polymerase chain reaction and a direct sequencing method. Of 23 hepatic malignant tumors, point mutations at K-ras codon 12 or K-ras codon 61 were found in six of nine cholangiocarcinomas. In contrast, there were no point mutations in any of 12 hepatocellular carcinomas or two hepatoblastomas around codon 12, 13, or 61 of the ras genes. These observations suggest that ras gene mutations are not related to pathogenesis of hepatocellular carcinoma, but play an important role in pathogenesis of cholangiocarcinoma.

1 To whom requests for reprints should be addressed, at First Department of Medicine, Chiba University School of Medicine, 1-8-1 Inohana, Chiba 280, Japan.

Received 6/13/89. Revised 10/11/89. Accepted 10/24/89.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Tada, F. Kanai, Y. Tanaka, K. Tateishi, M. Ohta, Y. Asaoka, M. Seto, R. Muroyama, K. Fukai, F. Imazeki, et al.
Down-Regulation of Hedgehog-Interacting Protein through Genetic and Epigenetic Alterations in Human Hepatocellular Carcinoma
Clin. Cancer Res., June 15, 2008; 14(12): 3768 - 3776.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. B. Thomas and J. L. Abbruzzese
Opportunities for Targeted Therapies in Hepatocellular Carcinoma
J. Clin. Oncol., November 1, 2005; 23(31): 8093 - 8108.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
Y. Kim, R. C. Sills, and C. D. Houle
Overview of the Molecular Biology of Hepatocellular Neoplasms and Hepatoblastomas of the Mouse Liver
Toxicol Pathol, January 1, 2005; 33(1): 175 - 180.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Harada, H. Oshima, M. Katoh, Y. Tamai, M. Oshima, and M. M. Taketo
Hepatocarcinogenesis in Mice with {beta}-Catenin and Ha-Ras Gene Mutations
Cancer Res., January 1, 2004; 64(1): 48 - 54.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Nakajima, T. Takayama, K. Miyanishi, A. Nobuoka, T. Hayashi, T. Abe, J. Kato, K. Sakon, Y. Naniwa, H. Tanabe, et al.
Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione S-Transferase-{pi}-Specific Inhibitor O1-Hexadecyl-{gamma}-glutamyl-S-benzylcysteinyl-D-phenylglycine Ethylester
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 861 - 869.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
J. Boix-Ferrero, A. Pellin, J. R. Blesa, M. Adrados, and A. Llombart-Bosch
K-ras Gene Mutations in Liver Carcinomas from a Mediterranean Area of Spain
International Journal of Surgical Pathology, October 1, 2000; 8(4): 267 - 270.
[Abstract] [PDF]

Home page
 Toxicol PatholHome page
D. Gulezian, D. Jacobson-Kram, C. B. Mccullough, H. Olson, L. Recio, D. Robinson, R. Storer, R. Tennant, J. M. Ward, and D. A. Neumann
Review Article: Use of Transgenic Animals for Carcinogenicity Testing: Considerations and Implications for Risk Assessment
Toxicol Pathol, May 1, 2000; 28(3): 482 - 499.
[Abstract] [PDF]

Home page
 GutHome page
Y Sirivatanauksorn, V Sirivatanauksorn, S Bhattacharya, B R Davidson, A P Dhillon, A K Kakkar, R C N Williamson, and N R Lemoine
Genomic heterogeneity in synchronous hepatocellular carcinomas
Gut, November 1, 1999; 45(5): 761 - 765.
[Abstract] [Full Text] [PDF]

Home page
 Genome ResHome page
D J Phillips, J M Benson, J M Pruckler, and W C Hooper
PCR regimen for enhanced specificity and yield of targeted genomic DNA sequences: ras and p53.
Genome Res., August 1, 1992; 2(1): 45 - 50.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.